Home > Dermatology > AAD 2020 > Pearls of the Posters > Spironolactone safe for androgenetic alopecia in cancer survivors

Spironolactone safe for androgenetic alopecia in cancer survivors

Presented By
Dr Chapman Wei, George Washington University, USA
Conference
AAD 2020
The potassium-sparing diuretic spironolactone is a viable treatment option in women with a previous breast cancer diagnosis [1]. In daily practice, spironolactone is often used off-label for the treatment of androgenetic alopecia in women. The agent exerts competitive blockade on androgen receptors in target tissues. It has been shown to arrest hair loss progression; a significant percentage of women even achieve partial hair regrowth [2]. However, limited data is available on its safety in breast cancer survivors. Due to its estrogenic effects, a potential risk for promoting cancer recurrence has been discussed. To clarify this issue, the authors performed a retrospective analysis using the Humana Insurance database. Breast cancer survivors were identified using ICD-9/10 codes and divided into cohorts by spironolactone prescription. Patient demographics and comorbidities were compared and analysed. Cohorts with and without spironolactone...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on